- Report
- April 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- May 2025
- 190 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- May 2025
- 195 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €2694EUR$3,000USD£2,294GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4489EUR$5,000USD£3,823GBP
- Report
- July 2024
- 100 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- July 2024
- 100 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4489EUR$5,000USD£3,823GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1122EUR$1,250USD£956GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- May 2025
- 110 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,148USD£1,587GBP
- Report
- July 2022
- 60 Pages
Global
From €600EUR$716USD£529GBP
- Report
- November 2021
- 222 Pages
Global
From €2694EUR$3,000USD£2,294GBP
- Report
- July 2022
- 165 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- March 2024
- 200 Pages
Global
From €3726EUR$4,150USD£3,173GBP
- Report
- July 2023
- 145 Pages
Global
From €2828EUR$3,150USD£2,408GBP
- Report
- June 2024
- 200 Pages
Global
From €7138EUR$7,950USD£6,079GBP
- Report
- October 2024
- 87 Pages
Spain
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- June 2024
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more